Literature DB >> 28550978

Left ventricular longitudinal strain impairment predicts cardiovascular events in asymptomatic type 1 myotonic dystrophy.

Rodrigue Garcia1, Michaela Rehman2, Cyril Goujeau2, Bruno Degand2, François Le Gal2, Benjamin Stordeur2, Quentin Labarre2, Luc Christiaens3, Claire Bouleti4.   

Abstract

BACKGROUND: Type 1 myotonic dystrophy (DM1) patients' prognosis is very poor. Up until now, only a few prognostic factors for cardiovascular events have been identified, and they are predictive of end-stage disease. The aim was to assess the prognostic value of global longitudinal strain (GLS) for cardiovascular events in asymptomatic DM1 patients.
METHODS: DM1 patients were included between 2011 and 2015 and followed up until January 2016. Patients underwent a transthoracic echocardiography at inclusion. The primary endpoint was a composite of all-cause mortality, type 2 Mobitz 2 and type 3 atrioventricular block, symptomatic sino-atrial block, HV interval≥70ms at invasive electrophysiology exploration, left ventricular ejection fraction (LVEF) ≤45% and newly developed atrial fibrillation.
RESULTS: Forty-six patients (25 males, mean age 40years old) were included. The primary outcome was reached in 14 patients with a mean follow-up of 38months. GLS of patients who reached the primary endpoint was significantly impaired as compared to those who did not (-15.1 [-16.7; -12.7] vs. -18.2 [-19.2; -16.7] respectively; P=0.001). According to ROC curve analysis, probability of primary outcome occurrence was significantly greater in patients with GLS values≥-17.2% (P=0.001). On multivariate analysis, PR electrocardiogram interval and GLS remained significantly and independently associated with the primary endpoint [hazard ratio (HR) 1.03, 95% confidence interval (CI) 1.01-1.04, P=0.006 for PR interval; HR 1.4, 95% CI 1.1-1.7, P=0.002 for GLS] while LVEF alone was not.
CONCLUSION: Left ventricular GLS is a powerful marker to predict cardiovascular events in asymptomatic DM1 patients, independently of LVEF.
Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Echocardiography; Left ventricular function; Multi-layer speckle tracking; Myotonic dystrophy type 1; Strain

Mesh:

Year:  2017        PMID: 28550978     DOI: 10.1016/j.ijcard.2017.05.061

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Non-invasive evaluation of the relationship between electrical and structural cardiac abnormalities in patients with myotonic dystrophy type 1.

Authors:  Lukas Chmielewski; Michael Bietenbeck; Alexandru Patrascu; Sabine Rösch; Udo Sechtem; Ali Yilmaz; Anca-Rezeda Florian
Journal:  Clin Res Cardiol       Date:  2019-02-14       Impact factor: 5.460

2.  Twenty-four-hour ambulatory ECG monitoring relevancy in myotonic dystrophy type 1 follow-up: Prognostic value and heart rate variability evolution.

Authors:  Alexandre Gamet; Bruno Degand; François Le Gal; Nicolas Bidegain; Anne Delaubier; Brigitte Gilbert-Dussardier; Luc Christiaens; Rodrigue Garcia
Journal:  Ann Noninvasive Electrocardiol       Date:  2018-08-12       Impact factor: 1.468

3.  Cardiac involvement in a cross-sectional cohort of myotonic dystrophies and other skeletal myopathies.

Authors:  Johannes Schmid; Meinrad Beer; Andrea Berghold; Tatjana Stojakovic; Hubert Scharnagl; Benjamin Dieplinger; Stefan Quasthoff; Josepha S Binder; Peter P Rainer
Journal:  ESC Heart Fail       Date:  2020-05-31

4.  Cardiac Involvement and Arrhythmias Associated with Myotonic Dystrophy.

Authors:  Daniel McBride; Amrish Deshmukh; Supriya Shore; Melissa A Elafros; Jackson J Liang
Journal:  Rev Cardiovasc Med       Date:  2022-04-02       Impact factor: 4.430

5.  Rare Disease: Cardiac Risk Assessment With MRI in Patients With Myotonic Dystrophy Type 1.

Authors:  Marco Alì; Caterina Beatrice Monti; Luca Melazzini; Rosanna Cardani; Barbara Fossati; Michele Cavalli; Kelvin Chow; Francesco Secchi; Giovanni Meola; Francesco Sardanelli
Journal:  Front Neurol       Date:  2020-03-19       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.